MIM
ALGS icon

MetLife Investment Management’s Aligos Therapeutics ALGS Stock Holding History

MetLife Investment Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-332
Closed -$98.6K – 2730
2021
Q4 		$98.6K Hold
332
– – ﹤0.01% 2411
2021
Q3 		$129K Hold
332
– – ﹤0.01% 2329
2021
Q2 		$169K Buy
+332
New +$212K ﹤0.01% 2256

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

MetLife Investment Management's ALGS Position: Q1 2022 in Review

MetLife Investment Management sold out of Aligos Therapeutics (ALGS) in Q1 2022, closing a stake of 332 shares — an estimated $98.6K sold.

MetLife Investment Management first reported a position in ALGS in Q2 2021 and held it in 3 quarters. The position peaked at $169K in Q2 2021. 76 funds tracked by Wall St. Rank hold ALGS as of Q1 2022.

  • MetLife Investment Management reported no remaining Aligos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • MetLife Investment Management sold 332 Aligos Therapeutics shares in Q1 2022, an estimated $98.6K.
  • MetLife Investment Management first reported a position in Aligos Therapeutics in Q2 2021 and held it in 3 quarters.
  • MetLife Investment Management's Aligos Therapeutics position peaked at $169K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.